Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors affecting outcome of acquired comitant esotropia with restricted use of digital devices: ACEDD Study 3.
Nishikawa N, Iimori H, Kinouchi R, Nishina S, Yoshida T, Hikoya A, Komori M, Hieda O, Goseki T, Mori T, Morimoto T, Negishi T, Shimizu T, Shimizu Y, Hayashi S, Sugiyama Y, Yokoyama Y, Kimura A, Suzuki H, Suzuki S, Azuma N, Sato M. Nishikawa N, et al. Among authors: nishina s. BMJ Open Ophthalmol. 2024 Oct 31;9(1):e001713. doi: 10.1136/bmjophth-2024-001713. BMJ Open Ophthalmol. 2024. PMID: 39486802 Free PMC article.
Outcomes of five cases of retinoblastoma with optic nerve invasion on imaging.
Onishi T, Nishina S, Yokoi T, Yoshida T, Hayashi S, Morikawa-Anzai H, Azuma N, Kiyotani C, Terashima K, Yoshioka T, Ogiwara H, Fuji H, Kitamura M, Tsutsumi Y. Onishi T, et al. Among authors: nishina s. Jpn J Ophthalmol. 2024 Nov;68(6):741-750. doi: 10.1007/s10384-024-01112-z. Epub 2024 Sep 28. Jpn J Ophthalmol. 2024. PMID: 39340727 Free PMC article.
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group. Saeki I, et al. Among authors: nishina s. PLoS One. 2024 Sep 25;19(9):e0311084. doi: 10.1371/journal.pone.0311084. eCollection 2024. PLoS One. 2024. PMID: 39321197 Free PMC article.
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T. Shimose S, et al. Among authors: nishina s. Oncol Lett. 2024 Jun 25;28(2):397. doi: 10.3892/ol.2024.14530. eCollection 2024 Aug. Oncol Lett. 2024. PMID: 38979550 Free PMC article.
230 results